Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00662714 | Early Diagnosis of Diabetes Mellitus in Patients With Cystic Fibrosis | PHASE3 | COMPLETED | 73 | — | — | Sep 1, 2001 | Dec 1, 2011 | Jul 10, 2012 | 36 | Austria, France +2 |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Repaglinide; oral |
| 2 | ACTIVE_COMPARATOR | short-acting Insulin (Actrapid) |
| Name | Type | Description |
|---|---|---|
| Repaglinide | DRUG | oral; initial dose: 3x 0.5mg/d; 2 years |
| short-acting Insulin (Actrapid) | DRUG | initial dose: 3x 0.05E/kg/d, injected; 2 years |
Inclusion Criteria: Inclusion Criteria for the Screening: * Diagnosed cystic fibrosis * Age 10 years and older Inclusion Criteria for the therapeutic part of the study: * Newly diagnosed Diabetes mellitus in the screening Exclusion Criteria: Exclusion Criteria for Screening: * Diabetic keto-a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 9 | PHASE3 | VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, VNZ/TEZ/D-IVA, VX-522 mRNA therapy |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719, SION-451, SION-2222, SION-109 |
| BiomX Ltd | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | — | Undisclosed |